First treatment recommended for rare immunoglobulin-related autoimmune disease

EMA’s human medicines committee (CHMP) has recommended extending the therapeutic indication of Uplizna (inebilizumab) to include the treatment of adult patients with active…

Leave a Reply

Your email address will not be published. Required fields are marked *